Protein Analysis for Clinical Diagnosis and Pharmaceutical Research
Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage, control efficacy of applied therapies in personalized medicine, examine efficacy of new drugs in preclinical (animal models) and clinical trials and to identify therapeutic targets.
The unique CE-MS technology displays peptides and proteins of body fluids. The generated pattern filed in a database provides a fast and authentic description of the individual health of an organism. Measurement of the proteome in combination with on-line database matching is the key to an all-in-one diagnosis for a wide spectrum of clinical applications.
DiaPat GmbH, a subsidiary of mosaiques diagnostics and therapeutics AG, markets successfully new diagnostic tests in Europe for Chronic Renal Diseases (including Diabetic Nephropathy), Bladder Cancer, Prostate Cancer, Cholangiocarcinoma, Coronary Artery Disease, Heart Failure, Ureteropelvic Junction Obstruction in Neonates and for early detection of Graft-versus-Host Disease, based on the technology described.